These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

473 related articles for article (PubMed ID: 24598411)

  • 1. Towards translational therapies for multiple system atrophy.
    Kuzdas-Wood D; Stefanova N; Jellinger KA; Seppi K; Schlossmacher MG; Poewe W; Wenning GK
    Prog Neurobiol; 2014 Jul; 118():19-35. PubMed ID: 24598411
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuropathology of multiple system atrophy: new thoughts about pathogenesis.
    Jellinger KA
    Mov Disord; 2014 Dec; 29(14):1720-41. PubMed ID: 25297524
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiple System Atrophy: An Oligodendroglioneural Synucleinopathy1.
    Jellinger KA
    J Alzheimers Dis; 2018; 62(3):1141-1179. PubMed ID: 28984582
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent advances in neuropathology, biomarkers and therapeutic approach of multiple system atrophy.
    Koga S; Dickson DW
    J Neurol Neurosurg Psychiatry; 2018 Feb; 89(2):175-184. PubMed ID: 28860330
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multiple system atrophy.
    Fanciulli A; Stankovic I; Krismer F; Seppi K; Levin J; Wenning GK
    Int Rev Neurobiol; 2019; 149():137-192. PubMed ID: 31779811
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiple system atrophy of the cerebellar type: clinical state of the art.
    Lin DJ; Hermann KL; Schmahmann JD
    Mov Disord; 2014 Mar; 29(3):294-304. PubMed ID: 24615754
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Models of multiple system atrophy.
    Fellner L; Wenning GK; Stefanova N
    Curr Top Behav Neurosci; 2015; 22():369-93. PubMed ID: 24338664
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progressive striatonigral degeneration in a transgenic mouse model of multiple system atrophy: translational implications for interventional therapies.
    Refolo V; Bez F; Polissidis A; Kuzdas-Wood D; Sturm E; Kamaratou M; Poewe W; Stefanis L; Angela Cenci M; Romero-Ramos M; Wenning GK; Stefanova N
    Acta Neuropathol Commun; 2018 Jan; 6(1):2. PubMed ID: 29298733
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A historical review of multiple system atrophy with a critical appraisal of cellular and animal models.
    Marmion DJ; Peelaerts W; Kordower JH
    J Neural Transm (Vienna); 2021 Oct; 128(10):1507-1527. PubMed ID: 34613484
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Mouse Model of Multiple System Atrophy: Bench to Bedside.
    Stefanova N
    Neurotherapeutics; 2023 Jan; 20(1):117-126. PubMed ID: 35995919
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiple system atrophy: the application of genetics in understanding etiology.
    Federoff M; Schottlaender LV; Houlden H; Singleton A
    Clin Auton Res; 2015 Feb; 25(1):19-36. PubMed ID: 25687905
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The neuropathology, pathophysiology and genetics of multiple system atrophy.
    Ahmed Z; Asi YT; Sailer A; Lees AJ; Houlden H; Revesz T; Holton JL
    Neuropathol Appl Neurobiol; 2012 Feb; 38(1):4-24. PubMed ID: 22074330
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current experimental disease-modifying therapeutics for multiple system atrophy.
    Lemos M; Wenning GK; Stefanova N
    J Neural Transm (Vienna); 2021 Oct; 128(10):1529-1543. PubMed ID: 34398313
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oligodendroglial alpha-synucleinopathy and MSA-like cardiovascular autonomic failure: experimental evidence.
    Kuzdas D; Stemberger S; Gaburro S; Stefanova N; Singewald N; Wenning GK
    Exp Neurol; 2013 Sep; 247():531-6. PubMed ID: 23399889
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Second consensus statement on the diagnosis of multiple system atrophy.
    Gilman S; Wenning GK; Low PA; Brooks DJ; Mathias CJ; Trojanowski JQ; Wood NW; Colosimo C; Dürr A; Fowler CJ; Kaufmann H; Klockgether T; Lees A; Poewe W; Quinn N; Revesz T; Robertson D; Sandroni P; Seppi K; Vidailhet M
    Neurology; 2008 Aug; 71(9):670-6. PubMed ID: 18725592
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Papp-Lantos inclusions and the pathogenesis of multiple system atrophy: an update.
    Jellinger KA; Lantos PL
    Acta Neuropathol; 2010 Jun; 119(6):657-67. PubMed ID: 20309568
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel therapeutic approaches in multiple system atrophy.
    Palma JA; Kaufmann H
    Clin Auton Res; 2015 Feb; 25(1):37-45. PubMed ID: 24928797
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current Symptomatic and Disease-Modifying Treatments in Multiple System Atrophy.
    Mészáros L; Hoffmann A; Wihan J; Winkler J
    Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32316335
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Insights into the pathogenesis of multiple system atrophy: focus on glial cytoplasmic inclusions.
    Kaji S; Maki T; Ishimoto T; Yamakado H; Takahashi R
    Transl Neurodegener; 2020; 9():7. PubMed ID: 32095235
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MSA: From basic mechanisms to experimental therapeutics.
    Heras-Garvin A; Stefanova N
    Parkinsonism Relat Disord; 2020 Apr; 73():94-104. PubMed ID: 32005598
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.